These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

1169 related items for PubMed ID: 6679957

  • 1. Physiological and physiochemical correction and prevention of calcium stone formation by potassium citrate therapy.
    Pak CY, Sakhaee K, Fuller CJ.
    Trans Assoc Am Physicians; 1983; 96():294-305. PubMed ID: 6679957
    [Abstract] [Full Text] [Related]

  • 2. Successful treatment of hyperuricosuric calcium oxalate nephrolithiasis with potassium citrate.
    Pak CY, Peterson R.
    Arch Intern Med; 1986 May; 146(5):863-7. PubMed ID: 3963975
    [Abstract] [Full Text] [Related]

  • 3. Long-term treatment of calcium nephrolithiasis with potassium citrate.
    Pak CY, Fuller C, Sakhaee K, Preminger GM, Britton F.
    J Urol; 1985 Jul; 134(1):11-9. PubMed ID: 3892044
    [Abstract] [Full Text] [Related]

  • 4. Reduction of renal stone risk by potassium-magnesium citrate during 5 weeks of bed rest.
    Zerwekh JE, Odvina CV, Wuermser LA, Pak CY.
    J Urol; 2007 Jun; 177(6):2179-84. PubMed ID: 17509313
    [Abstract] [Full Text] [Related]

  • 5. Alkaline citrate in prevention of recurrent calcium oxalate stones.
    Berg C.
    Scand J Urol Nephrol Suppl; 1990 Jun; 130():1-83. PubMed ID: 2291093
    [Abstract] [Full Text] [Related]

  • 6. Metabolic abnormalities associated with calyceal diverticular stones.
    Auge BK, Maloney ME, Mathias BJ, Pietrow PK, Preminger GM.
    BJU Int; 2006 May; 97(5):1053-6. PubMed ID: 16643491
    [Abstract] [Full Text] [Related]

  • 7. The effects of potassium and magnesium supplementations on urinary risk factors of renal stone patients.
    Jaipakdee S, Prasongwatana V, Premgamone A, Reungjui S, Tosukhowong P, Tungsanga K, Suwantrai S, Noppawinyoowong C, Maskasame S, Sriboonlue P.
    J Med Assoc Thai; 2004 Mar; 87(3):255-63. PubMed ID: 15117041
    [Abstract] [Full Text] [Related]

  • 8. Stone forming risk of calcium citrate supplementation in healthy postmenopausal women.
    Sakhaee K, Poindexter JR, Griffith CS, Pak CY.
    J Urol; 2004 Sep; 172(3):958-61. PubMed ID: 15311008
    [Abstract] [Full Text] [Related]

  • 9. Prevention of stone formation and bone loss in absorptive hypercalciuria by combined dietary and pharmacological interventions.
    Pak CY, Heller HJ, Pearle MS, Odvina CV, Poindexter JR, Peterson RD.
    J Urol; 2003 Feb; 169(2):465-9. PubMed ID: 12544288
    [Abstract] [Full Text] [Related]

  • 10. Hypocitraturia as a pathogenic risk factor in the mixed (calcium oxalate/uric acid) renal stones.
    Alvarez Arroyo MV, Traba ML, Rapado A.
    Urol Int; 1992 Feb; 48(3):342-6. PubMed ID: 1589930
    [Abstract] [Full Text] [Related]

  • 11. Dietary treatment of urinary risk factors for renal stone formation. A review of CLU Working Group.
    Prezioso D, Strazzullo P, Lotti T, Bianchi G, Borghi L, Caione P, Carini M, Caudarella R, Ferraro M, Gambaro G, Gelosa M, Guttilla A, Illiano E, Martino M, Meschi T, Messa P, Miano R, Napodano G, Nouvenne A, Rendina D, Rocco F, Rosa M, Sanseverino R, Salerno A, Spatafora S, Tasca A, Ticinesi A, Travaglini F, Trinchieri A, Vespasiani G, Zattoni F, CLU Working Group.
    Arch Ital Urol Androl; 2015 Jul 07; 87(2):105-20. PubMed ID: 26150027
    [Abstract] [Full Text] [Related]

  • 12. Citrate and renal calculi.
    Pak CY.
    Miner Electrolyte Metab; 1987 Jul 07; 13(4):257-66. PubMed ID: 3306318
    [Abstract] [Full Text] [Related]

  • 13. Changes in urinary stone risk factors in hypocitraturic calcium oxalate stone formers treated with dietary sodium supplementation.
    Stoller ML, Chi T, Eisner BH, Shami G, Gentle DL.
    J Urol; 2009 Mar 07; 181(3):1140-4. PubMed ID: 19152919
    [Abstract] [Full Text] [Related]

  • 14. Idiopathic hypocitraturic calcium-oxalate nephrolithiasis successfully treated with potassium citrate.
    Pak CY, Fuller C.
    Ann Intern Med; 1986 Jan 07; 104(1):33-7. PubMed ID: 3940503
    [Abstract] [Full Text] [Related]

  • 15.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 16. [Influence of urinary citrate levels on spontaneous calcium oxalate dihydrate crystalluria].
    Hassani MA, Hennequin C, Lacour B, Daudon M.
    Prog Urol; 2005 Sep 07; 15(4):650-5. PubMed ID: 16459680
    [Abstract] [Full Text] [Related]

  • 17. Urinary lithogen risk test: usefulness in the evaluation of renal lithiasis treatment using crystallization inhibitors (citrate and phytate).
    Conte A, Pizá P, García-Raja A.
    Arch Esp Urol; 1999 Sep 07; 52(1):94-9. PubMed ID: 10101897
    [Abstract] [Full Text] [Related]

  • 18.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 19. Prevention of recurrent nephrolithiasis.
    Goldfarb DS, Coe FL.
    Am Fam Physician; 1999 Nov 15; 60(8):2269-76. PubMed ID: 10593318
    [Abstract] [Full Text] [Related]

  • 20. Urine citrate and renal stone disease.
    Goldberg H, Grass L, Vogl R, Rapoport A, Oreopoulos DG.
    CMAJ; 1989 Aug 01; 141(3):217-21. PubMed ID: 2665909
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 59.